Suppr超能文献

一项在接受新辅助化疗的可切除和边界可切除胰腺癌患者中使用部分覆膜金属支架的前瞻性多中心研究:BTS-NAC 研究。

A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: BTS-NAC Study.

机构信息

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.

Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

出版信息

Gut Liver. 2021 Jan 15;15(1):135-141. doi: 10.5009/gnl19302.

Abstract

BACKGROUND/AIMS: The aim of this study was to evaluate the safety and efficacy of partially covered self-expandable metallic stents (PCSEMS) in patients undergoing neoadjuvant chemo(radio) therapy (NAC) for pancreatic cancer (PC).

METHODS

This was a prospective multicenter study to evaluate the safety and efficacy of PCSEMS in patients receiving NAC for resectable and borderline resectable PC. The primary endpoint was the rate of recurrent biliary obstruction (RBO).

RESULTS

Twenty-six patients with PC (three with resectable PC and 23 with borderline resectable PC) who underwent NAC at seven Japanese centers were included in the analysis. Both the technical and functional success rates of PCSEMS placement were 100%. Early stent-related complications were observed in three patients (11.5%): mild pancreatitis (n=2) and mild liver abscess (n=1). The median time to surgery or palliation was 4.0 months. Surgical resection was eventually performed in 73.1% of patients, and stent removal during surgery was successful in all patients. RBO was observed in nine patients (34.6%): seven with stent occlusion, one with kinking and one with migration. The RBO rates in resected cases and nonresected cases were 36.8% and 28.6%, respectively.

CONCLUSIONS

Biliary drainage by PCSEMS was safe and feasible in patients undergoing NAC for resectable and borderline resectable PC.

摘要

背景/目的:本研究旨在评估在接受新辅助化疗(放化疗)的胰腺癌(PC)患者中使用部分覆膜自膨式金属支架(PCSEMS)的安全性和疗效。

方法

这是一项前瞻性多中心研究,旨在评估在接受可切除和交界可切除 PC 新辅助化疗的患者中使用 PCSEMS 的安全性和疗效。主要终点是复发性胆道梗阻(RBO)的发生率。

结果

在 7 个日本中心接受 NAC 的 26 例 PC 患者(3 例可切除 PC,23 例交界可切除 PC)纳入分析。PCSEMS 放置的技术和功能成功率均为 100%。3 名患者(11.5%)出现早期支架相关并发症:轻度胰腺炎(n=2)和轻度肝脓肿(n=1)。手术或姑息治疗的中位时间为 4.0 个月。最终有 73.1%的患者接受了手术切除,所有患者在手术中均成功取出支架。9 名患者(34.6%)出现 RBO:7 例支架阻塞,1 例支架扭结,1 例支架迁移。在切除病例和未切除病例中,RBO 发生率分别为 36.8%和 28.6%。

结论

在接受可切除和交界可切除 PC 新辅助化疗的患者中,PCSEMS 胆道引流是安全可行的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6f6/7817930/d68e29bbd397/gnl-15-1-135-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验